CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future ...

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and ...

Zydus Lifesciences reacted sharply to the development in Tuesday's trade with the counter rising 5.23 percent to an intraday high of Rs 1,011.75 per share on the NSE.

A state law that went into effect this week aims to regulate the role of third-party pharmacy benefit managers, who many say ...

Bullish option flow detected in CVS Health (CVS) with 33,211 calls trading, 1.7x expected, and implied vol increasing over 7 points to 47.44%.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

CVS Health Corp. closed $34.74 short of its 52-week high ($80.75), which the company reached on March 28th.

CVS Health CVS shareholders are experiencing a rough period as the stock continues to face significant downward pressure. Recent reports about the company's strategic restructuring plans have ...